Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGC-1503
- Development stage
- Unknown
- Lead developer
- BioKey
01
Overview
Experimental oncology drug candidate from Rgene Corporation being guided through development by ABVC BioPharma’s subsidiary (BioKey) under a Clinical Development Service Agreement; designated for treatment of colorectal cancer through completion of Phase II clinical studies under U.S. FDA IND requirements. Specific target, modality, and mechanism of action have not been publicly disclosed in the cited materials.[1][9][7][3]
Beyond the preview
Go deeper on RGC-1503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGC-1503.